Gibson Christopher 4

What Happened

• Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), sold 40,000 shares in an open‑market transaction on May 22, 2026, at $3.08 per share for proceeds of $123,200.
• The filing also shows conversion entries: 40,000 shares were converted from Class B Common Stock into Class A Common Stock (reported at $0.00 because this was a share‑class conversion, not a cash purchase), and those converted shares were then sold. The conversion is 1:1 per the filing footnotes.
• This is a sale (liquidity event) executed under a prearranged Rule 10b5‑1 trading plan adopted by Gibson on May 12, 2025.

Key Details

• Transaction date: May 22, 2026. Sale price: $3.08 per share. Proceeds: $123,200.
• Reported actions: conversion of 40,000 Class B shares to Class A (C, reported at $0.00) and an open‑market sale of 40,000 Class A shares (S).
• 10b5‑1 plan: The sale was made pursuant to a Rule 10b5‑1 trading plan (footnote F1).
• Share‑class conversion: Each Class B share converts into one Class A share (footnotes F2/F3); conversion entries reflect that conversion rather than a paid acquisition.
• Holdings after the transaction: Not specified in the provided Form 4 summary. The filing references holdings held through related entities (LAHWRAN‑3 LLC, LAHWRAN‑4 LLC) and the Gibson Family Trust (footnotes F4–F6).
• Filing: Form 4 filed May 27, 2026 (accession 0001856369-26-000019). The provided data does not flag a late‑report code.

Context

• This was not an options exercise for cash: the $0.00 conversion amounts reflect share‑class conversion (Class B → Class A), not a zero‑cost acquisition of new economic value.
• The sale was executed under a preexisting 10b5‑1 plan, which is a predetermined trading arrangement often used to avoid the appearance of trading on material, nonpublic information.
• Sales by insiders are often routine liquidity events; they do not, by themselves, prove a change in the insider’s view of the company.